الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 248 |  |  |
| | | from | 248 | | |
Abstract
This study aimed to evaluate the role of new chromene derivative (EAPBC) in treatment of alloxan induced diabetes in rats. Also, to investigate the activity of some newly biomarker such as, fetuin A and, netrin 1 in type 2 diabetes induced by alloxan in rats.
To perform this study adult male albino rats weighing 200-280 g.
Diabetes was induced by Monohydrated alloxan. Diabetes mellitus (DM) was induced in overnight-fasted rats by a single i.p. injection of freshly-prepared alloxan monohydrate, dissolved in a cold physiological saline (0.9% NaCl) solution at the dose rate of 150 mg/kg body weight. The animals were given free access to 5% glucose solution in order to overcome the alloxan-induced hypoglycaemia for the first one-hour post-treatment with alloxan.
50 adult male albino rats were divided into 5 groups.
group I (control group, rats were orally administered with 1 ml saline daily). GroupII (DMSO group, rats were orally administered with 0.2 % DMSO for 40 days).
group III (standard group, diabetic animals treated with 100 mg/kg b. wt of metformin for 40 days orally).
group IV (therapeutic group, diabetic rats treated orally with 50 mg /kg b. wt of cromen for 40 days).
group V (positive control, animals were injected intraperitoneal with 150 mg/kg b. wt. alloxan).
The results were concluded to that cromen (EABCC) exhibits anti-hyperglycemic and anti-lipidimic in alloxan induced diabetic rats. Also, suggests that Fetuin A and Netrin 1 bio markers may be used as pre diagnosis type 2 diabetes induced by alloxan in rats.